Description
Pazopanib is an inhibitor of VEGFR, PDGFR, and c-Kit that displays anticancer chemotherapeutic and anti-angiogenic activities. Pazopanib is clinically used to treat metastatic renal cell carcinoma, but shows potential for a wide variety of other cancers, including ovarian cancer and non-small cell lung cancer (NSCLC). In vitro and in vivo, pazopanib inhibits cell proliferation and angiogenesis, preventing tumor growth. This compound also inhibits wild-type B-Raf, preventing activation of p-ERK1/2 and p-MEK1/2, decreasing brain metastasis volume in animal models of breast cancer.
